[Comparative efficiency study, safety and usage of tested drugs in patients with renal colic].
Renal colic represents the the collection of the acute symptoms which are characterized by very intensive and antagonizing pain, so, that withstanding, it calls for fast diagnosis and precise and speedy treatment. Intervention in renal colic cases has to be based on the knowledge on the origin of pain, renal damage suffered, and also has to protect the kidney from any damaged caused by the prolonged obstruction.


METHODS
This paper presents the results from prospective, analitical, comparative, ITT (intention to treat) study that has been carried out 200 ambulatory treated seperate patients with renal colic, divided into four groups, in the time period from year 2003 to 2005. In all these cases the the efficiency and the active time time of standard medications used with renal colic symptoms.


RESULTS
2 grams of Metamizol i.v. and 75 mg of Diclofenac i.m. have shown equal efficiency in pain relief, which is 6 hours after the administration of therapy, while 50 mg of Butylscopolamin i.v. requires additional analgesic treatment (p < 0.05). The effect of Metamizol is a bit stronger 15 minutes after the application than the rest of the medications, but 30 minutes after the application the effects of Metamizol and Diclofenac are almost identical. Using meta analasys and EBM (Evidence Based Medicine) parameters in regard to the side effects, the made conclusion was that Diclofenac is the medication of choice for renal colic. Reserve medication is Metamizol, while Butylscopolamin causes negative side effects in 84% of the cases, and in 24% of the cases it causes cupping of the renal colic.
Prcić
Alden
A
Uroloska Klinika, Klinicki Centar Univerziteta u Sarajevu.
Aganović
Damir
D
Junuzović
Dzelaludin
D
Kulovac
Benjamin
B
D000293:Adolescent; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D002086:Butylscopolammonium Bromide / Q000627:therapeutic use; D002648:Child; D003085:Colic / Q000188:drug therapy*; D004008:Diclofenac / Q000627:therapeutic use; D004177:Dipyrone / Q000627:therapeutic use; D006801:Humans; D007674:Kidney Diseases / Q000188:drug therapy*; D008875:Middle Aged; D010147:Pain Measurement; D010276:Parasympatholytics / Q000627:therapeutic use
D000894:Anti-Inflammatory Agents, Non-Steroidal; D010276:Parasympatholytics; D004008:Diclofenac; D002086:Butylscopolammonium Bromide; D004177:Dipyrone